Megapharm Revenue and Competitors

USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Megapharm's estimated annual revenue is currently $22.1M per year.(i)
  • Megapharm's estimated revenue per employee is $201,000

Employee Data

  • Megapharm has 110 Employees.(i)
  • Megapharm grew their employee count by -4% last year.

Megapharm's People

NameTitleEmail/Phone
1
Product managerReveal Email/Phone
2
Logistics ManagerReveal Email/Phone
3
Regulatory Affairs AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Megapharm?

Megapharm Ltd., founded in 1989, is one of the leading private biotech marketing company in Israel engaged in the pharmaceutical and healthcare business. Megapharm represents a number of well known international companies. Since its inception, Megapharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in select therapeutic areas and diversified segments of the healthcare business. Megapharm management team has a proven track record and well established business relationships with decision makers in the Health Funds and Ministry of Health. This is crucial to the maintenance of successful business results. The team also has close links with opinion leaders and researchers in various therapeutic areas which enable a smoother entrance of new products into the Israeli market. Sales and promotional activities are carried out by our knowledgeable and well managed sales force that covers the entire country.

keywords:N/A

N/A

Total Funding

110

Number of Employees

$22.1M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A11010%$278M
#2
$7.5M110-23%N/A
#3
$29.7M1107%N/A
#4
$36.3M1104%N/A
#5
$19.8M11034%N/A